S ystemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of autoantibodies against nuclear antigens and an ongoing type I interferon production, which causes inflammation in multiple organ systems and increased mortality in the patients. 1,2 Already in the 1970s, a bimodal mortality pattern was seen in SLE with early deaths caused by active disease complicated by infections and a later peak of mortality caused by myocardial infarction. 3 Subsequent studies demonstrated a 10-fold increased risk of myocardial infarction in SLE, 4 and women with SLE between 35 and 44 years of age have an up to 50-fold increased risk of myocardial infarction compared with the general population. 5
antiphospholipid antibodies, 9 impaired renal function, 10 increased endothelial cell apoptosis, 11 improper endothelial repair, 12 decreased activity of lipoprotein lipases, 13 SLE-related treatment such as high doses of steroids, 14 and the impact of an ongoing type I interferon production, 15 can all contribute to the increased incidence of cardiovascular disease in these patients. However, the exact role of the different risk factors in the cardiovascular disease process in SLE is unknown.
In recent years, considerable progress in defining risk loci for SLE 16 has been made through the candidate gene and genome-wide association studies, and >40 of the identified SLE risk alleles have been convincingly replicated. 17 Most risk genes are located in immune-related pathways, such as antigen presentation, the interferon system, and T-and B-cell receptor signaling. 18 Progress has also been made in linking subphenotypes of SLE with single-nucleotide polymorphisms (SNPs). For instance, SNPs in STAT4, interferon regulatory factor-5 (IRF5), and ITGAM have been associated with the presence of double-stranded DNA autoantibodies, 19, 20 and an allele variant in HLA-DR3 has been associated with renal disease. 21 We recently identified a STAT4 risk allele that was associated with cerebrovascular disease in SLE, which affects 10% of the patients with SLE. 22 We also observed an association between the STAT4 risk allele and prothrombotic antiphospholipid antibodies, possibly creating a mechanistic link to stroke. However, in that study, we did not observe any association between the STAT4 risk loci and the presence of coronary heart disease (CHD). To further investigate a possible genetic risk of CHD in SLE, we genotyped 2 SLE populations using a custom-designed panel of 5676 SNPs selected from regions that had showed nominally significant association signals with SLE in a genome-wide study. 16 Next, we performed an association study, looking for SNPs associated with CHD, in the first patient study population and replicated the SNPs that showed a strong association with CHD (P<0.01) in the second study population. We also performed carotid ultrasound on a subgroup of patients and evaluated a possible connection between the CHD risk alleles and intima-media thickness (IMT) or the presence of plaques. Finally, we performed flow cytometric staining of peripheral blood mononuclear cells (PBMCs) for the protein of the identified risk gene variant, IRF8.
Methods

Study Populations
Two SLE populations were investigated: (1) study population 1 constituted the discovery population and included 575 patients from the rheumatology clinics at Uppsala, Karolinska (Stockholm), and Lund University Hospital, Sweden; and (2) study population 2 (replication population) included 239 patients with SLE from the 4 northern-most counties in Sweden. Patient characteristics are given in Table 1 . If patients were related, only the first case in each family was included. A rheumatologist examined all patients and their medical records. All patients were self-described individuals of European descent and fulfilled ≥4 American College of Rheumatology (ACR) criteria for the diagnosis of SLE. 23 Organ damage was determined using the Systemic Lupus International Collaborating Clinics/ACR damage index. 24 The regional ethics committees approved the study, and all participants gave their informed consent.
CHD was defined as previous myocardial infarction, diagnosed by increased plasma troponin T or creatine kinase, muscle and brain fraction, and 1 of the following: symptoms of ischemia, ECG changes, development of pathological Q wave or new regional wall motion abnormality, 25 or angina pectoris (confirmed by exercise stress test), in line with the definition by Luepker et al. 26 The population controls (n=532) in the case-control analysis were matched for age and sex and consisted of healthy blood donors (Uppsala, Lund) and controls from the population-based Epidemiological Investigation of Rheumatoid Arthritis cohort (Stockholm). 27
Genotyping
All patients in both study populations were genotyped using custom 12k Illumina iSelect BeadArrays, as previously described by Gateva et al. 27 The SNPs included in the array had been selected from loci with P<0.05 in an SLE genome-wide association scan, 16 previously reported SLE risk loci, and confirmed risk loci in other autoimmune diseases. 27 The genotype data had passed rigorous genotype quality control, including the removal of population outliers. In this study, we included SNPs with <5% missing data, a Hardy-Weinberg equilibrium P>1×10 -6 , and minor-allele frequency >0.01%. A total of 5676 SNPs remained for analysis after quality control filters and exclusion of ancestry informative markers.
Carotid Ultrasound
Ultrasound scans were performed in 203 patients with SLE within study population 1 (Stockholm and Uppsala) using a duplex scanner with a linear array transducer. Scans were digitalized for off-line analysis. Pictures were frozen incident with the R wave on the ECG. The IMT was defined as the distance between the leading edge of the luminal echo and the leading edge of the media/adventitia echo. 28 Measurements were made on the far wall of both the left and the right distal common carotid arteries, which equals an average of the wall thickness on 1-cm length of the vessel ending 0.5 to 1.0 cm from the bifurcation. The IMT is a mean calculated from the intima-media area divided by the calculated length (10 mm) on 1 scan. Values are mean measurement from both the right and the left carotid. Plaques were defined as a local increase in wall thickness of >1 mm and >100% increase in wall thickness compared with adjacent wall.
Statistical Analysis
Allelic association tests were performed using a 1 degree of freedom χ 2 test, and independent effects were assessed using a logistic regression model including the allelic dosage for the SNP rs925994 as covariate, both using the PLINK software version 1.07 29 (http://pngu. mgh.harvard.edu/~purcell/plink/). Meta-analysis was performed using standard methods based on the Cochrane-Mantel-Haenszel test using PLINK version 1.07. Categorical variables were compared with χ 2 test and continuous variables with Mann-Whitney U test using Statistica 9.1 (StatSoft Inc, Tulsa, OK). Univariate and multivariable logistic regression analyses were performed using SPSS version 19.0. The Haploview v.4.2 software was used to determine linkage disequilibrium (LD) between the polymorphisms 30 in the HapMap data, 1000 Genome data, and in the data from study population 1. Quanto v1.2.4 (http://hydra.usc.edu/gxe/) was used to estimate power assuming a log additive model, a 2-sided type 1 error rate 0.05, a risk allele frequency of 0.035, and a prevalence of CHD of 11.5% for study population 1 and 11.3% for study population 2. The power analysis showed a power of >90% to detect an association at an odds ratio (OR) of 3.7 in study population 1, a power of >50% to detect an association at an OR of 3.4 in study population 2, and a power of >96% to detect an association at an OR of 3.6 for the meta-analysis.
Flow Cytometry
PBMCs were purified from ethylenediaminetetraacetic acidanticoagulated blood obtained from patients with SLE (nonrisk allele=13; risk allele=7) or healthy individuals (n=10) by using Ficoll-Hypaque (GE Healthcare) density gradient centrifugation. A total of 1×10 6 PBMCs were first stained with monoclonal antibodies to cell-specific markers, APC-BDCA2 (Miltenyi Biotec), FITC-CD3, Per-CP5.5-CD19, APC-Cy7-CD14, and PECy7-CD56 (BD Bioscience), fixed with 1% paraformaldehyde in phosphate-buffered saline for 10 minutes, and then stained for intracellular IRF8 with a polyclonal goat antibody (sc-6058; Santa Cruz Biotechnology) in the presence of 0.5% saponin.
Isotype-matched immunoglobin G (DakoCytomation) was used as a control antibody. Finally, the cells were stained with a PE-antigoat mAb (R&D Systems) and analyzed by flow cytometry with a FACSCanto II instrument (BD Biosciences) and Diva Software 6.1.3 (BD Biosciences). Cells were first gated as singlets followed . The exons are shown as vertical bars labeled 1 to 9, with the position of the SNPs indicated by thin lines. The SNPs rs925994 and rs10514610 were found to be associated with coronary heart disease with P<1×10 −5 in the present study. The SNPs rs2280381, 32 rs4843869, 33 rs450443, 33 rs11644034, 33 and rs8046523 33 have been associated with SLE in previous studies. The SNPs rs305079, rs401528, rs428530, rs437740, rs438323, rs452352, rs3794661, rs3794662, rs16939917, and rs11117415 are in high linkage disequilibrium (r 2 >0.50) with rs925994 or rs10514610 and were tested for potential differences in protein binding using electrophoretic mobility shift assays. The SNPs rs5818563 and rs34727451 represent 2 insertion-deletion polymorphisms with high conservation scores in the region. UTR indicates untranslated region.
by gating of IRF8-positive populations. Antigen expression levels were quantified on the basis of median fluorescence intensity.
Electrophoretic Mobility Shift Assay
The alleles of 14 SNPs were subjected to electrophoretic mobility shift assay (EMSA), as previously described. 31 These SNPs included the 2 SNPs found to be associated with CHD: rs925994 and rs10514610; 10 additional SNPs in relatively high LD (r 2 >0.50) with the SNPs rs925994 or rs10514610 (HapMap Data Rel 28): rs305079, rs401528, rs428530, rs437740, rs438323, rs452352, rs3794661, rs3794662, rs16939917, and rs11117415 ( Figure I in the online-only Data Supplement); and 2 insertion-deletion polymorphisms located in the flanking region of the 2 associated SNPs and with high conservation scores: rs5818563 and rs34727451 ( Figure 1 ). For EMSA, pairs of single-stranded oligonucleotides (Integrated DNA Technologies) with the SNP positioned in the center flanked by 15 bases were annealed to generate double-stranded probes. One of the oligonucleotides was 5ʹ biotinylated, and the other was unlabelled. Nuclear extract was prepared from human PBMCs from a healthy blood donor using the NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo Scientific Pierce Protein Research). Ten femtomoles of labeled probes, nuclear extract from 1.5×10 6 PBMCs, and 2 µg of poly(deoxyinosinic-deoxycytidylic) acid were incubated in freshly made binding buffer at 20°C for 20 minutes. For competition assays, 500-fold molar excess of unlabelled probes were added to the reaction mixtures. Free probes and probe-protein complexes were separated on 6% polyacrylamide gels (Invitrogen) and transferred to nylon membranes (GE Healthcare). The Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific Pierce Protein Research) was used for signal detection.
Protein-Binding Motif Prediction
Potential protein-binding motifs were predicted by comparing the sequence of 1 SNP allele and 10 bases of flanking sequence with the known motifs in the JASPAR CORE 2009 database using the software Motif Comparison Tool (TOMTOM). 34 
Results
Identification of IRF8 as a Risk Loci for CHD in SLE
The 2 study populations of patients with SLE were clinically similar, as described by the ACR criteria ( Table 1 ). The prevalence of CHD, diabetes mellitus, and smoking (ever) was also comparable, whereas hypertension (treated) was more common in study population 2. Patients in study population 1 were younger at the time of diagnosis and had a longer SLE disease duration, but the age at follow-up was similar in both populations.
Initially, we compared the allele frequencies of 5676 SNPs in 1960 gene regions in patients with SLE with and without a history of CHD in study population 1. We found 61 SNPs in 50 gene regions that were associated with CHD (P<0.01). The strongest association signal was observed for 3 SNPs, rs925994, rs419030, and rs10514610, located in IRF8. In addition, another 2 SNPs in IRF8 were associated with P<0.01 ( Table I in the online-only Data Supplement) . Next, we compared the allele frequencies of these 61 SNPs in patients with and without CHD in study population 2 ( Table  I in the online-only Data Supplement). Two SNPs located in IRF8 with similar allele frequencies in both study populations, rs925994 and rs10514610, were also associated with CHD in study population 2. Meta-analysis of the SNP with the strongest association to CHD (rs925994) in both study populations gave an OR of 3.6 (2.1-6.3), P value 1.9×10 -6 ( Table 2 ). The 2 SNPs, rs925994 and rs10514610, are in LD (r 2 = 0.84), and conditioning on rs925994 showed no independent effect (P=0.63). Therefore, we conclude that the 2 SNPs represent the same signal. Both SNPs are located in introns: rs925994 in intron 4 and rs10514610 in intron 2 of IRF8 (Figure 1 ). These SNPs are not in LD with any of the previously published SNPs located in IRF8 that have shown signals of association with SLE ( Figure I in the online-only Data Supplement). One of the SNPs in IRF8, previously associated with SLE, 32 rs2280381, was included on the genotyping array used in this study but showed no association with CHD (P=0.23). Furthermore, when comparing the allele frequencies of SNPs rs925994 and rs10514610 between patients with SLE (study population 1, n=575) and population controls (n=532), no association with SLE was detected (P=0.89 and 0.91).
In study populations 1 and 2, a total of 28% and 18% of the patients with SLE carrying the risk allele (T) of rs925994 had a history of CHD compared with 10% and 7% in the patients without the risk allele. Results of the comparison between patients with or without the risk allele in study population 1 are shown in the online-only Data Supplement Table II . Patients were diagnosed with CHD on average 7 years before follow-up, and no difference was seen between the groups. Three patients were homozygous for the risk allele rs925994, and each of these individuals had a history of CHD. We found no association between the SNP rs925994 risk allele and ischemic cerebrovascular disease, venous thromboembolism, or any of the ACR criteria, except that leukopenia was more prevalent in patients with the nonrisk allele. The Systemic The 3 SNPs with the strongest association to CHD in study population 1. The results replicated in study population 2. Unadjusted P values are given. CHD indicates coronary heart disease; CI, confidence interval; IRF, interferon regulatory factor; MAF, minor-allele frequency; M/m, major/minor alleles; OR, odds ratio; SLE, systemic lupus erythematosus; and SNP, single-nucleotide polymorphism.
*Sixty-six patients with SLE with CHD and 509 patients without CHD. †Twenty-seven patients with CHD and 212 without CHD. ‡SLE with CHD/ SLE without CHD.
Lupus International Collaborating Clinics/ACR damage index was elevated in the group with the risk allele, but when adjusting for CHD, no difference was observed between the groups.
In conclusion, we have demonstrated a strong association between CHD in SLE and risk variants of IRF8 (OR=3.6), which are not linked with SLE per se or with major organ involvement such as nephritis.
An IRF8 Risk Allele Is Associated With Increased IMT and Presence of Plaque
To investigate whether the IRF8 risk allele was associated with increased atherosclerosis in SLE, a subgroup of patients with SLE in study population 1 was examined by carotid ultrasound. The presence of plaque was determined and the IMT was measured. Patients with the risk allele of SNP rs925994 had carotid plaques more frequently (50%) than patients without the risk allele (18%; P=0.001; Table 3 ). Furthermore, the IMT was significantly thicker in the risk allele group (0.658 mm) compared with the nonrisk allele group (0.596 mm; P=0.01). No difference between the groups was observed for factors affecting the IMT such as age or sex ( Table III in the online-only Data Supplement). In addition, there was no major difference in medication.
Multivariable Regression Analysis
To determine the relationship between known CHD risk factors and the IRF8 risk alleles, data, including age, sex, smoking (ever), hypertension (treated), diabetes mellitus, SLE disease duration, and the SNP rs925994 in study population 1, were entered into a multivariable logistic model. No information about the lipid profile was available. After adjustment for these traditional CHD risk factors, the association between the IRF8 risk allele and CHD remained unaltered ( 
IRF8 Intracellular Staining
PBMCs from patients with SLE with and without the risk allele rs925994 and healthy individuals were stained for intracellular IRF8 and analyzed by flow cytometry. We found that only a minority of PBMCs expressed IRF8 (median [Q1-Q3]; healthy 1.2% [0.6%-4.9%], SLE 2.1% [0.9-4.3%]) and that there was no difference between patients with or without the risk allele (data not shown). However, IRF8 was highly expressed in plasmacytoid dendritic cells (pDCs) and at a lower level in a proportion of B cells ( Figure III in the onlineonly Data Supplement). Next, we analyzed the frequency of B cells and pDC, as well as the IRF8 expression in these cell types. Patients with the rs925994 risk allele had a lower frequency of B cells compared with patients without the risk allele (P<0.05) or healthy controls (P<0.01; Figure 2A ) while the IRF8 expression was highest among patients with SLE with the risk allele ( Figure 3B ). Patients with the risk allele showed a trend to reduced pDC frequency and IRF8 expression intensity ( Figure 2C and 2D ).
Differential Binding in an Electrophoretic Mobility Shift Assay
To investigate the potential difference in protein binding between the IRF8 risk alleles and nonrisk alleles, we performed an EMSA analysis. We included the 2 IRF8 SNPs, 10 SNPs in relatively high LD with these SNPs, and 2 insertion-deletion polymorphisms in the region. Of these SNPs and insertiondeletion polymorphisms, rs11117415 showed allelic differences in binding with proteins in the nuclear extract from PBMCs (Figure 3 ), suggesting differential binding of transcriptions factors with IRF8. The observed protein binding was weaker for the rs11117415 risk allele (G). Furthermore, a suggestive weaker protein binding was seen for the rs925994 risk allele (T). On the basis of known protein-binding motifs in the JASPAR CORE 2009 database, 4 possible transcription factors were identified. They are nuclear transcription factor Y α, high-mobility group box transcription factor 1 for rs11117415, nuclear factor (erythroid-derived 2)-like 2, and regulatory factor X 4 for rs925994 ( Figure II in the onlineonly Data Supplement).
To further investigate the role of the SNP rs11117415, we looked for association with CHD using data from the 12k Illumina iSelect BeadArrays previously described. The SNP rs11117415 showed an association to CHD in both study population 1 (P=0.02) and study population 2 (P=0.007), and a meta-analysis gave an OR of 2.5 (1.4-4.3; P=4.8×10 −4 ).
Discussion
In this study, we present a strong association between polymorphisms in IRF8 and CHD in 2 independent SLE study populations. Both study populations comprise well-characterized patients with a similar prevalence of CHD of 11%, which is in line with previous published data on the prevalence of CHD in an unselected population of patients with SLE. 24 The first patient study population was from 3 university hospitals, whereas many patients in the second study population were from county hospitals. The difference in patient recruitment might explain the differences in age at diagnosis and Systemic Lupus International Collaborating Clinics/ACR damage scores between the 2 study populations. Despite this, there were no major differences regarding the ACR criteria between the 2 study populations, and the age at follow-up was identical for both groups. We, therefore, conclude that the results in the present investigation are representative for patients with SLE of northern European descent.
A number of risk alleles at the IRF8 locus have been associated with SLE, 32, 33 but so far no association to a specific disease phenotype has been reported for any IRF8 gene variant. The reasons for this could be that most studies focus on disease manifestations described by the ACR criteria and that the SNPs identified by us are rare in the general SLE population and not in LD with any of the SNPs previously found to be associated with SLE. In this study, no difference was observed between patients with and without the IRF8 risk allele in ACR criteria, except for leukopenia, or Systemic Lupus International Collaborating Clinics/ACR criteria adjusted for CHD. Consequently, the increased prevalence of CHD in the group of patients carrying the risk allele does not seem to be caused by a more severe SLE disease in these individuals. In addition, when adjusting for established CHD risk factors, such as hypertension, age, diabetes mellitus, and smoking, the risk locus remained as a substantial risk factor for CHD. Unfortunately, we did not have information regarding lipid profile, but to our knowledge, there are no studies indicating that IRF8 is involved in lipid metabolism. Taken together, these observations support the conjecture that the indentified IRF8 alleles represent an independent risk factor for CHD in SLE.
The possible role of IRF8 in the development of cardiovascular disease is unknown, and no association between SNPs in IRF8 and CHD has been reported at genome-wide significance in studies of CHD in the genome-wide association studies catalogue in www.genome.gov/gwastudies/ or the Coronary ARtery DIsease Genome-wide Replication and Meta-analysis plus Coronary Artery Disease Consortium. 35 This finding could indicate that the identified IRF8 risk alleles in our study have not been thoroughly investigated in the general population with CHD or that the risk alleles only are operative in patients with a chronic autoimmune disease such as SLE. Nevertheless, the observed association of the IRF8 risk alleles with increased IMT and presence of carotid plaque in patients with SLE indicates that there is a true link between the risk gene variants and the development of atherosclerosis. The association is intriguing also given the recently reported increased atherosclerosis in ApoE −/− mice transplanted with IRF8 −/− bone marrow. 36 In this study, the IRF8 −/− mice displayed an increased number of polymorphonuclear neutrophilic leukocytes possibly exacerbating inflammation in local plaques. Furthermore, a reduced number of monocytes was detected, and macrophages had a reduced expression of MHC II, CD40, and surface class B scavenger receptor CD36. This limits macrophage clearance of apoptotic cells and the anti-inflammatory functions, which promoted arteriosclerotic lesion formation. It remains to be established whether the IRF8 risk alleles in our study can affect the function of polymorphonuclear neutrophilic leukocytes or contribute to the reduced clearance of apoptotic cells typically seen in SLE.
In this study, patients with the risk allele less often had leukopenia compared with patients with the nonrisk allele. This observation is at variance with the finding that patients with the risk allele displayed a reduced frequency of circulating B cells and also a slightly decreased frequency of pDCs. The reasons for these findings are unclear, but 1 possibility is that IRF8 mainly acts in infrequent subsets of PBMCs and contributes to cell type-specific functions. This assumption is supported by the observation that the expression of IRF8 was mainly detected in B cells and pDCs. Because IRF8 is important for the development of B cells and their function in germinal centers, 37,38 the IRF8 risk allele might contribute to an accumulation of B cells in lymphoid tissues and a reduced number in the circulation. Similarly, the IRF8 risk allele could play a role in tissue migration of pDCs, a possibility supported by the fact that pDCs are important in the development of plaques, and such cells can also be found in atherosclerotic lesions. 39 However, further studies in experimental models are needed to clarify the functional role of the IRF8 risk allele in B cells and pDCs.
Using EMSA, we also demonstrated allelic differences in protein binding for the risk allele of SNPs rs11117415 and possibly also for rs925994 located in putative binding sites for the transcription factors such as nuclear transcription factor Y α, high-mobility group box transcription factor 1, nuclear factor (erythroid-derived 2)-like 2, and regulatory factor X 4 that might regulate the transcription of IRF8 in an allele-specific manner. Furthermore, rs925994 and rs10514610 are in high LD with 5 additional SNPs located in a region 6 kb upstream of the 5′-untranslated region of IRF8. This region contains possible binding sites for transcription factors, such as histone acetyltransferase p300 and paired box protein Pax-5 and might be an enhancer region for IRF8. Obviously, the results from EMSA are suggestive and would need to be confirmed by other methods.
IRF8, previously known as consensus sequence-binding protein, is a transcriptional activator or repressor that forms DNA-binding complexes with several partners, including the interferon regulatory factor family, the E-26 family, and transcription factor E2-α. 37 These complexes regulate the expression of multiple genes involved in, for example, cytokine signaling, cell cycle regulation, and differentiation. 37 In B cells, there are a large number of IRF8 target genes, many of which are with importance in the molecular crosstalk among germinal center immune cells. 40 IRF8 also binds to TRAF6 and is required for TLR9 signaling in pDCs where it promotes type I interferon production. 38 In addition, IRF8 helps to prolong the recruitment of transcription factors to the interferon promoters and thereby amplifies the interferon production. 41 Because interferon-α via several different mechanisms 12, 15, [42] [43] [44] [45] [46] is important in the development of atherosclerosis in SLE, 16 the IRF8 risk gene variants may contribute to the increased CHD incidence in SLE by affecting the function of the type I interferon system. This includes potential effects on pDCs and also B cells, which are dependent on IRF8 for differentiation and function. Considering the accumulating evidences for an important role of these cells in atherosclerosis, 36, 39, [47] [48] [49] it therefore seems important to clarify possible effects by the identified IRF8 risk variants in the arteriosclerotic disease process in SLE.
Conclusions
In 2 separate patient populations, we demonstrate that 2 linked SNPs in IRF8 are strongly associated with CHD in SLE. The SNPs are not associated with SLE per se, but independently with CHD in this patient group and when adjusting for a number of known CHD risk factors, the association of the IRF8 locus remains unaltered.
